Artivion, Inc.
AORT

$1.11 B
Marketcap
$26.44
Share price
Country
$0.52
Change (1 day)
$29.24
Year High
$12.16
Year Low
Categories

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

marketcap

P/E ratio for Artivion, Inc. (AORT)

P/E ratio as of 2023: -23.83

According to Artivion, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -23.83. At the end of 2022 the company had a P/E ratio of -25.28.

P/E ratio history for Artivion, Inc. from 1991 to 2023

PE ratio at the end of each year

Year P/E ratio
2023 -23.83
2022 -25.28
2021 -53.48
2020 -53.58
2019 584.61
2018 -262.26
2017 170.65
2016 56.60
2015 74.68
2014 42.37
2013 18.44
2012 21.14
2011 17.87
2010 38.46
2009 20.79
2008 8.20
2007 29.07
2006 520.39
2005 -4.10
2004 -8.69
2003 -3.52
2002 -4.78
2001 61.56
2000 71.75
1999 32.58
1998 21.88
1997 27.95
1996 30.46
1995 33.71
1994 24.07
1993 52.08
1992 57.14
1991 -50.00